Use of cell-permeable peptides to prevent neuronal degeneration

Trends in Molecular Medicine

Volumn 10, Issue 5, 2004, Pages 239-244

  Borsello, Tiziana ^a,b   Bonny, Christophe ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

CELL MEMBRANE PERMEABILITY; ENZYME INHIBITION; HUMAN; NERVE CELL DEGENERATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL MEMBRANE PERMEABILITY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION;

EID: 2342573044     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.03.008     Document Type: Review

References (43)

1. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3:2002;663-672
2. Whitmarsh A.J., et al. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science. 281:1998;1671-1674
3. Kelkar N., et al. Interaction of a mitogen-activated protein kinase signaling module with the neuronal protein JIP3. Mol. Cell. Biol. 20:2000;1030-1043
4. Tournier C., et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 288:2000;870-874
5. Yang D.D., et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 389:1997;865-870
6. Bhalla U.S., Iyengar R. Emergent properties of networks of biological signaling pathways. Science. 283:1999;381-387
7. Carboni L., et al. Differential expression of SAPK isoforms in the rat brain. An in situ hybridisation study in the adult rat brain and during post-natal development. Brain Res. Mol. Brain Res. 60:1998;57-68
8. Kuan C.Y., et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 22:1999;667-676
9. Mielke K., et al. Selective expression of JNK isoforms and stress-specific JNK activity in different neural cell lines. Brain Res. Mol. Brain Res. 75:2000;128-137
10. Schauwecker P.E. Seizure-induced neuronal death is associated with induction of c-Jun N-terminal kinase and is dependent on genetic background. Brain Res. 884:2000;116-128
11. Herdegen T., Waetzig V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene. 20:2001;2424-2437
12. Xu X., et al. Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12655-12660
13. Coffey E.T., et al. Dual roles for c-Jun N-terminal kinase in developmental and stress responses in cerebellar granule neurons. J. Neurosci. 20:2000;7602-7613
14. Wu W., et al. Effect of batroxobin on expression of c-Jun in left temporal ischemic rats with spatial learning and memory disorder. J. Tradit. Chin. Med. 20:2000;147-151
15. Magara F., et al. Increased vulnerability to kainic acid-induced epileptic seizures in mice underexpressing the scaffold protein Islet-Brain 1/JIP-1. Eur. J. Neurosci. 17:2003;2602-2610
16. Raghupathi R., et al. Acute activation of mitogen-activated protein kinases following traumatic brain injury in the rat: implications for posttraumatic cell death. Exp. Neurol. 183:2003;438-448
17. Zhu X., et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76:2001;435-441
18. Behrens A., et al. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat. Genet. 21:1999;326-329
19. Kuan C.Y., et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:2003;15184-15189
20. Borsello T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9:2003;1180-1186
21. Martin-Villalba A., et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19:1999;3809-3817
22. Sugino T., et al. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J. Neurosci. 20:2000;4506-4514
23. Bozyczko-Coyne D., et al. Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr. Drug Target CNS Neurol Disord. 1:2002;31-49
24. Hawiger J. Noninvasive intracellular delivery of functional peptides and proteins. Curr. Opin. Chem. Biol. 3:1999;89-94
25. May M.J., et al. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science. 289:2000;1550-1554
26. Bonny C., et al. Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes. 50:2001;77-82
27. Joliot A., Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell Biol. 6:2004;189-196
28. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572
29. Gius D.R., et al. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res. 59:1999;2577-2580
30. Willam C., et al. Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;10423-10428
31. Sugioka R., et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene. 22:2003;8432-8440
32. Ye H., et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 418:2002;443-447
33. Aarts M., et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 298:2002;846-850
34. Asoh S., et al. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A. 99:2002;17107-17112
35. Kilic E., et al. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann. Neurol. 52:2002;617-622
36. Cao G., et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:2002;5423-5431
37. Barr R.K., et al. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277:2002;10987-10997
38. Brugidou J., et al. The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: a new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Commun. 214:1995;685-693
39. Tong L., et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4:1997;311-316
40. Bennett B.L., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13681-13686
41. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4:2003;49-60
42. Hallbrink M., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta. 1515:2001;101-109
43. Wang J., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci. 23:2003;8596-8607